http://www.miraclemulti.com MiracleMulti™ The Best Multivitamins on the market for Men, Women, Vegetarians, and Bodybuilding. Once a day Multivitamin for Health, Energy, Focus, Well Being and Anti-aging.***These statements have not been evaluated by the Food and Drug Administration. This product is not intended to diagnose, treat, cure, or prevent any disease.
Money Management International (MMI) is participating in a nationwide partnership to help families struggling with their mortgage payments apply for help from the Federal government’s Making Home Affordable Program (MHA). The MHA program is an important part of the Obama administration’s comprehensive plan to help homeowners get mortgage relief and avoid foreclosure.
To view Multimedia News Release, go to http://www.multivu.com/mnr/52440-money-management-international-mmi-mortgage-relief-mha-program
Miramar Labs today announced that the miraDry System for the treatment of primary axillary hyperhidrosis, commonly known as excessive underarm sweat, is now available to select physicians in the U.S. The miraDry procedure provides a safe and lasting solution for this debilitating condition.
The U.S. Food & Drug Administration granted clearance for miraDry following a robust, randomized, blinded clinical study that involved 120 patients at seven clinics and followed them 12-months post treatment. The miraDry System delivers energy non-invasively to the area under the arm where the sweat glands reside which creates localized heat to destroy and eliminate the glands. Since sweat glands do not regenerate, results are lasting.
To view Multimedia News Release, go to http://www.multivu.com/mnr/54021-miramar-labs-miradry-treat-excessive-underarm-sweat-axillary-hyperhidrosis
Spring is around the corner, and it won’t be long before it’s prom and graduation seasons for many high schoolers. Rites of passage for many, these are times for teens to celebrate, but can also be times of poor decision-making, especially when vehicles are involved. The National Highway Traffic Safety Administration (NHTSA) reports that 2,524 teen drivers and passengers were killed and 177,000 were injured in 2013. Twenty-seven percent of these fatalities occurred between April and June, according to the Insurance Institute for Highway Safety (IIHS).
“The statistics are staggering, especially when you consider that most of these accidents and fatalities are preventable,” said Randy Petro, Mercury Insurance’s chief claims officer. “We don’t want any families to suffer through the loss of a child, so Mercury is taking action with the launch of the ‘Mercury Insurance Drive Safe Challenge.’”
The Mercury Insurance Drive Safe Challenge kicked off with a free defensive driving program, which included hands-on driving skills training and classroom material. An interactive website provides teens with detailed instruction, as well as gives parents the tools to shape responsible driving behavior.
To view the multimedia release go to:
http://www.multivu.com/players/English/7772251-mercury-teen-drive-safe-challenge/
In recognition of Melanoma Monday® and National Melanoma/Skin Cancer Detection & Prevention MonthTM, MELA Sciences, Inc. (NASDAQ: MELA) visited the NASDAQ MarketSite in Times Square today to ring the Opening Bell and sponsor free skin cancer checks.
One American dies every hour from melanoma, the most deadly skin cancer. MELA Sciences, Inc. is the pioneer company behind MelaFind®, the first and only FDA-approved diagnostic tool that helps dermatologists detect melanoma at its most curable stage. MelaFind® was approved by the U.S. Food & Drug Administration (FDA) in Fall 2011, and since then has strategically rolled out the technology to dermatology practices across the country.
To view Multimedia News Release, go to http://www.multivu.com/mnr/61584-mela-sciences-rings-opening-bell-awareness-melanoma-detection-prevention
Boston Scientific (NYSE: BSX) has received U.S. Food and Drug Administration (FDA) approval for the SYNERGY™ Bioabsorbable Polymer Drug-Eluting Stent System (BP-DES) for the treatment of coronary artery disease.
With this FDA approval, Boston Scientific will commence commercialization of the first and only BP-DES in the U.S. Notably, both the drug coating and the polymer – which modulates drug release – are fully absorbed shortly after drug elution is complete at three months.
The SYNERGY Stent provides synchronized drug and polymer absorption. It is designed to enable more rapid and complete arterial healing, and to thereby reduce the risk of complications associated with long-term polymer exposure compared to currently-used drug-eluting stents (DES) with permanent polymers.
To view the multimedia release go to:
http://www.multivu.com/players/English/7223456-boston-scientific-fda-approval-synergy/
The U.S. Food and Drug Administration (FDA) is alerting pregnant women about the risks of listeriosis, a foodborne disease that can severely affect a pregnant women and her unborn child.
Listeria can affect all races and ethnic groups, but pregnant women are 10 times more likely than other healthy adults to get listeriosis due to hormonal changes that affect the immune system during pregnancy. Pregnant Hispanic women are about 24 times more likely than the general population to get listeriosis. A pregnant mother may pass Listeria onto her unborn baby without even knowing it because she doesn’t feel sick at all, yet the disease can lead to miscarriage, stillbirth, premature labor, the delivery of a low birthweight infant, a wide range of health problems for a newborn, or even infant death.
To view the multimedia release go to:
https://www.multivu.com/players/English/7953451-fda-listeriosis-prevention-pregnant-women/
Dune Medical Devices, Inc., announced today that its breakthrough intra-operative tissue assessment tool for early-stage breast cancer surgery, the MarginProbe System, has received Premarket Approval (PMA) by the United States Food and Drug Administration. The technology significantly improves surgeons’ ability to intra-operatively identify
Lytx®, Inc., the global leader in video-based driver safety, unveiled today a giant leap forward in safe driving innovation with its Lytx ActiveVision℠ service available for select Lytx DriveCam™ clients immediately, and industry-wide in January 2016. The ActiveVision service will be publicly demonstrated this weekend at the 2015 American Trucking Associations Management Conference & Exhibition in Philadelphia.
The ActiveVision service is a revolutionary and comprehensive safety solution that helps detect and address, both in real time and over time, distracted and drowsy driving and following too close, all potentially dangerous and costly driving behaviors that often go undetected -- behaviors that contribute to 6,000 deaths, 500,000 injuries, and more than $175 billion in economic costs each year, according to the National Highway Traffic Safety Administration.
To view the multimedia release go to:
http://www.multivu.com/players/English/7277351-lytx-activevision-distracted-driving/
Allergan, Inc. (NYSE: AGN), the makers of LATISSE® (bimatoprost ophthalmic solution) 0.03%, announced today the launch of the LATISSE® Wishes Challenge campaign. Inspired by the tradition of blowing on an eyelash to make wishes come true, lifestyle designer Kathy Ireland, professional ballroom dancer Chelsie Hightower and style guide Bobbie Thomas will each lead teams of LATISSE® users from across the country who are challenged to raise more than a quarter of a million dollars for the Make-A-Wish Foundation, a nonprofit organization dedicated to granting the wishes of children with life-threatening medical conditions. LATISSE® solution is the first and only prescription treatment approved by the U.S. Food and Drug Administration (FDA) to grow lashes longer, fuller and darker for those with inadequate or not enough lashes (eyelash hypotrichosis).
To view Multimedia News Release, go to http://multivu.prnewswire.com/mnr/latisse/43354/
Abbott announced today the U.S. Food and Drug Administration approval and launch of the iDesign Advanced WaveScan Studio System. The system acts as the "brain" of the LASIK procedure, generating a high-definition scan that measures and maps irregularities of the eye that may impact vision. From these measurements, the iDesign System creates an accurate and personalized LASIK treatment plan based on the unique "blueprint" of each person’s eyes.
The iDesign System captures more than 1,200 micro readings of the eye, as well as identifying the shape of the cornea, its curvature, how light passes through the eye and pupil diameter under different lighting conditions – all in one, three-second scan that can be used to precisely correct vision.
The development of the sensor technology within the iDesign System was the result of an earlier discovery by Abbott scientists, which NASA used to accurately measure and shape the mirrors in the James Webb Space Telescope to ensure it will transmit high resolution images of deep space back to earth. The telescope is scheduled to launch in 2018.
To view the Multimedia News Release, please go to http://www.multivu.com/players/English/7571951-abbott-idesign-system-3-d-eye-map/
As Child Passenger Safety Week wraps up, the U.S. Department of Transportation's National Highway Traffic Safety Administration (NHTSA) is launching a new Car Seat Finder Tool, adding the ability to look up car seat recalls on its mobile app, and reminding parents and caregivers to register their child's car seat through its new campaign – “Don't Delay. Register Your Car Seat Today.” Every 34 seconds, a child under the age of 13 is involved in a crash and more than a third of children killed in crashes were not in car seats or wearing seat belts. NHTSA's new Car Seat Finder Tool is aimed at helping parents select the right car seat or booster seat for their child, while the campaign reminds everyone of the importance of registering car seats to receive important safety recall notifications.
To view the Multimedia News Release, go to http://www.multivu.com/players/English/7310151-ad-council-nhtsa-child-passenger-safety-2014/
